It's been difficult to track Xtandi sale to this point because Medivation and Astellas have been trying to block prescription data from third-party tracking services. Note that Xtandi was approved on Aug. 31, leaving just four weeks of third-quarter sales.

Xtandi consensus for the fourth quarter is $25-30 million, although whisper number is closer to $40 million based on the limited prescription data available.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Vertex Pharmaceuticals Could Be Headed Higher Once Again

Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

10 High-Yielding Stocks to Own Ahead of a Surprising Late Summer Market Swoon

Vertex Pharmaceuticals: Looking East, West and to the Quants

Vertex Pharmaceuticals: Looking East, West and to the Quants